The Evidence Blog

Recent Posts

Rising Obesity Rates in U.S. Children and Adolescents

Posted by The Evidence Blog on July 10, 2018

The percentage of children and adolescents affected by obesity has more than tripled since the 1970s, according to the CDC; nearly 1 in 5 American youth are obese. According to data from the National Health and Nutrition Examination Survey, around 18% of youth ages 2 to 19 years were obese and nearly 6% were severely obese in 2015-2016. Rates of obesity and severe obesity in adolescents (ages 12 to 19 years) are even higher.

Read More

FDA Approves First Cannabis-Derived Drug for Treatment of Seizures

Posted by The Evidence Blog on July 5, 2018

The Food and Drug Administration (FDA) last week approved Epidiolex (cannabidiol; GW Pharmaceuticals) for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older. This is the first FDA-approved drug that contains a purified drug substance derived from marijuana; it’s also the first FDA approval of a drug for the treatment of patients with Dravet syndrome.

Read More

Topics: FDA approval, Epidiolex

FDA’s Efforts to Support Value-Based Healthcare

Posted by The Evidence Blog on June 27, 2018

Innovative medical treatments are being developed at an astonishing pace. However, rising medical costs are a roadblock to patient access to many of these innovations. Last month, Secretary of Health and Human Services Alex Azar rolled out a blueprint to address this challenge. The blueprint highlights the importance of linking payments for medical treatments to their value and removing regulatory obstacles to value-based purchasing.

Read More

Topics: FDA, value based healthcare

FDA Approves Palynziq for Treatment of Phenylketonuria

Posted by The Evidence Blog on June 15, 2018

Recently, the FDA approved Palynziq (pegvaliase-pqpz; BioMarin Pharmaceutical Inc.), a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations on existing management. 

Read More

FDA Expands Indications for Senhance Surgery System

Posted by The Evidence Blog on June 15, 2018

With the promise of shorter hospital stays, less blood loss, less pain, fewer complications from surgery, and a quicker return to normal activities for most patients, many hospitals and healthcare systems are embracing the use of robotic surgery systems. 

Read More

FDA Approves New Drug to Treat Thrombocytopenia in Chronic Liver Disease

Posted by The Evidence Blog on June 14, 2018

The FDA has approved Doptelet (avatrombopag; AkaRx Inc.), a drug used for the treatment of thrombocytopenia in adult patients with chronic liver disease who have low blood platelets and are scheduled to undergo a medical or dental procedure. This is the first drug approved by the FDA for this use.  

Read More

FDA Approves First-in-Class Medicine for Migraine Prevention

Posted by The Evidence Blog on June 14, 2018

The FDA has approved Aimovig (erenumab-aooe; Amgen and Novartis) for the preventive treatment of migraine in adults. Aimovig is an injectable calcitonin gene-related peptide (CGRP) antagonist.

Read More

Evidence Provides a Framework for Genetic Testing

Posted by The Evidence Blog on July 20, 2017

Clinical applications of genetic/genomic testing are potentially important but, as others have observed, “the current knowledge base . . . to turn the promise of genomic medicine into reality is severely limited.”

Read More

Topics: Hayes Blog, Genetic Testing

Getting to Know Hayes: Marco Angeli, Innovation Product Owner

Posted by The Evidence Blog on June 20, 2017

Hayes is a company of real people. We’d like you to get to know us and the ways we strive to provide personalized service to you, our clients. This month, let us introduce you to another valuable contributor to the Hayes mission of providing fiercely-unbiased evidence, and our product owner of client-led product innovation. Meet Marco Angeli.

Read More

Topics: Hayes Blog, Innovation

Getting to Know Hayes: Beth Bontemps, Product Manager, Prognosis and News Service

Posted by The Evidence Blog on April 19, 2017

Hayes is a company of real people and we’d like you to get to know us. This month, we introduce you to another valuable contributor to the Hayes mission of providing fiercely unbiased evidence. Meet Beth Bontemps.

Ms. Bontemps joined Hayes in September 2014 as a Senior Analyst. In 2017, she was promoted to the position of Product Manager, Prognosis and News Service.

She comes to Hayes from JR Associates Inc., a medical technology reimbursement consulting firm where she worked as a clinical and reimbursement consultant. 

Read More

Topics: Hayes Blog

Sign up to receive updates from our blog

Our latest articles

New Call-to-action